Camp4 Therapeutics: Needham initiates coverage with buy rating; target price $8
CAMP•Needham initiated coverage of Camp4 Therapeutics with a buy rating and an $8 target price.
Related News
Kinetik Holdings raises target price to $59 from $58
KNTK•
Banks need 'bare metal' recovery in face of AI risks, says BoE's Breeden
XLF•
Prudential cuts Binastra stake to 7.696%
PUK•
Redwire Corporation: Piper Sandler initiates coverage with neutral rating; price target $11
RDW•
Gold climbs over 1% on softer dollar, yields ahead of US inflation data
GLD•